Abstract: Anhydrous device in the form of a closed shell containing a fatty phase, the shell and the fatty phase constituting the necessary ingredients and in an amount adequate for the extemporaneous preparation of a single-use cosmetic emulsion, solely by adding water.
Abstract: Use of an oral pharmaceutical composition to reduce the intestinal passage effect on the active principle contained in, the said composition being in the form of a system which is self-microemulsifying on contact with an aqueous phase, comprising:
Type:
Application
Filed:
January 23, 2004
Publication date:
July 29, 2004
Applicant:
Gattefosse Holding
Inventors:
Hassan Benameur, Vincent Jannin, Delphine Marchaud
Abstract: A pharmaceutical composition for oral use is disclosed. It includes, as active principle, a drug liable to undergo a strong first intestinal passage effect and a carrier which is self-micro-emulsifying on contact with an aqueous phase. The carrier includes:
a therapeutically effective amount of the active principle;
a lipophilic phase, which is a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group comprising C8-C18 fatty acids;
a surfactant phase which is a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C8) and capric acid (C10);
a co-surfactant phase which is an ester of a polyvalent alcohol with at least one fatty acid chosen from the group comprising caprylic esters of propylene glycol, lauric esters of propylene glycol and oleic esters of polyglycerol. A method of decreasing the effect of intestinal metabolism on a drug using the composition is also disclosed.
Type:
Grant
Filed:
August 22, 2001
Date of Patent:
November 25, 2003
Assignee:
Gattefosse Holding
Inventors:
Hassan Benameur, Vincent Jannin, Delphine Roulot